Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Prevalence of metabolic syndrome in patients with pulmonary hypertension
Ussavarungsi, Kamonpun , Thomas, Colleen S. , Burger, Charles D.

The Clinical Respiratory Journal | October 23, 2015 | Volume: 11 | Issue: 6 | Pages: 721-726

10.1111/crj.12406 | PMID 26493968 Get It

AbstractBackground and AimsTo determine the prevalence of metabolic syndrome (MetS) – a potential phenotypical risk for pulmonary hypertension (PH) – in patients with PH and by PH diagnostic group including group 1 pulmonary arterial hypertension (PAH); group 1.1 idiopathic PAH, groups 1.2 heritable PAH, 1.3 drug and toxin induced, 1.4 associated PAH, group 2 PH with left heart disease, group 3 PH associated with lung disease and/or hypoxemia, group 4 PH owing to chronic thrombotic and/or embolic disease, and group 5 PH from multifactorial mechanisms.MethodsWe conducted a retrospective chart review of patients referred to Mayo Clinic in Florida from January 1990 to October 2013 (N = 1287). Only patients whom PH was confirmed by right heart catheterization were included (N = 640). MetS was defined with at least three of the following: systemic hypertension, diabetes mellitus, hyperlipidemia and body mass index > 30.ResultsMetS was prevalent in 247 of 640 (39%) with PH: 13% in group 1.1 PAH, 12% in groups 1.2–1.4 PAH, 54% in group 2, 55% in group 3, 23% in group 4 and 24% in group 5. After adjusting for age, sex and race, diagnostic subgroup analysis revealed a higher prevalence of MetS in WHO Group 2 PH patients [adjusted odd ratios (OR): 2.58, P < 0.0001] and WHO group 3 PH (adjusted OR: 2.77, P < 0.0001) when compared to group 1 PH.ConclusionThe prevalence of MetS was observed in 39% of patients with PH; however, among PH patients, the prevalence was higher in group 2 and 3 PH.
3‐Deoxyschweinfurthin B Lowers Cholesterol Levels by Decreasing Synthesis and Increasing Export in Cultured Cancer Cell Lines
Kuder, Craig H., Weivoda, Megan , Neighbors, Jeffrey D. , Wiemer, David F. , Hohl, Raymond J., Weivoda, Megan M, Zhang, Ying , Zhu, Junjia , Neighbors, Jeffrey

Lipids | October 23, 2015 | Volume: 50 | Issue: 12 | Pages: 1195-1207

10.1007/s11745-015-4083-z | PMID 26494560 Get It

AbstractThe schweinfurthins have potent antiproliferative activity in multiple glioblastoma multiforme (GBM) cell lines; however, the mechanism by which growth is impeded is not fully understood. Previously, we demonstrated that the schweinfurthins reduce the level of key isoprenoid intermediates in the cholesterol biosynthetic pathway. Herein, we describe the effects of the schweinfurthins on cholesterol homeostasis. Intracellular cholesterol levels are greatly reduced in cells incubated with 3‐deoxyschweinfurthin B (3dSB), an analog of the natural product schweinfurthin B. Decreased cholesterol levels are due to decreased cholesterol synthesis and increased cholesterol efflux; both of these cellular actions can be influenced by liver X‐receptor (LXR) activation. The effects of 3dSB on ATP‐binding cassette transporter 1 levels and other LXR targets are similar to that of 25‐hydroxycholesterol, an LXR agonist. Unlike 25‐hydroxycholesterol, 3dSB does not act as a direct agonist for LXR α or β. These data suggest that cholesterol homeostasis plays a significant role in the growth inhibitory activity of the schweinfurthins and may elucidate a mechanism that can be targeted in human cancers such as GBM.
Time From Symptoms to Carotid Endarterectomy or Stenting and Perioperative Risk
Hopkins, L. Nelson , Altafullah, Irfan, Wechsler, Lawrence R. , Gonzales, Nicole R. , Voeks, Jenifer H. , Howard, George , Brott, Thomas G. , Stotts, Grant, Meschia, James F. , Stotts, Grant , Howard, George

Stroke | October 23, 2015 | Volume: 46 | Issue: 12 | Pages: 3540-3542

10.1161/strokeaha.115.011123 | PMID 26493675 Get It

Background and Purpose— Prior meta-analysis showed that carotid endarterectomy benefits decline with increasing surgical delay following symptoms. For symptomatic patients in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST), we assessed if differences in time between symptoms and carotid endarterectomy or carotid artery stenting are associated with differences in risk of periprocedural stroke or death. Methods— We analyzed the 1180 symptomatic patients in CREST who received their assigned procedure and had clearly defined timing of symptoms. Patients were classified into 3 groups based on time from symptoms to procedure: <15, 15 to 60, and >60 days. Results— For carotid endarterectomy, risk of periprocedural stroke or death was not significantly different for the 2 later time periods relative to the earliest time period (hazard ratio, 0.74; 95% confidence interval, 0.22–2.49 for 15–60 days and hazard ratio, 0.91; 95% confidence interval, 0.25–3.33 for >60 days; P =0.89). For carotid artery stenting, risk of periprocedural stroke or death was also not significantly different for later time periods relative to the earliest time period (hazard ratio, 1.12; 95% confidence interval, 0.53–2.40 for 15–60 days and hazard ratio, 1.15; 95% confidence interval, 0.48–2.75 for >60 days; P =0.93). Conclusions— Time from symptoms to carotid endarterectomy or carotid artery stenting did not alter periprocedural safety, supporting early revascularization regardless of modality. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00004732.
Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma
Jaïs, Jean‐Philippe , Ghesquières, Hervé , Thompson, Carrie A. , Thiéblemont, Catherine , Micallef, Ivana N. , Porrata, Luis F. , Nowakowski, G. S., Casasnovas, Olivier , Bologna, Serge, Morrison, Vicki A., Macon, William R. , Copie‐Bergman, Christiane , Feldman, Andrew L. , Syrbu, Sergei , Kurtin, Paul J. , Gascoyne, Randy D. , Li, Hailun , Allmer, Cristine, Ansell, Stephen M. , Link, Brian K. , Salles, Gilles , Tilly, Hervé , Nowakowski, Gregorz S, Maurer, Matthew J. , Witzig, Thomas E. , Hong, Fangxin , Haïoun, Corinne , Ribrag, Vincent , Morschhauser, Franck , Peterson, Bruce A. , Kahl, Brad S. , Slager, Susan L. , Habermann, Thomas M. , Cerhan, James R. , Feldman, Andrew L , Link, Brian K , Salles, Gilles A , Syrbu, Sergei , Casasnovas, René-Olivier

American Journal of Hematology | October 22, 2015 | Volume: 91 | Issue: 2 | Pages: 179-184

10.1002/ajh.24223 | PMID 26492520 Get It

We recently defined event‐free survival at 24 months (EFS24) as a clinically relevant outcome for patients with DLBCL. Patients who fail EFS24 have very poor overall survival, while those who achieve EFS24 have a subsequent overall survival equivalent to that of the age‐ and sex‐matched general population. Here, we develop and validate a clinical risk calculator (IPI24) for EFS24. Model building was performed on a discovery dataset of 1,348 patients with DLBCL and treated with anthracycline‐based immunochemotherapy. A multivariable model containing age, Ann Arbor stage, normalized serum LDH, ALC, ECOG performance status, bulky disease, and sex was identified. The model was then applied to an independent validation dataset of 1,177 DLBCL patients. The IPI24 score estimates the probability of failing to achieve the EFS24 endpoint for an individual patient. The IPI24 model showed superior discriminatory ability (c‐statistic = 0.671) in the validation dataset compared to the IPI (c‐statistic = 0.649) or the NCCN‐IPI (c‐statistic = 0.657). After recalibration of the model on the combined dataset, the median predicted probability of failing to achieve EFS24 was 36% (range, 12–88%), and the IPI24 showed an EFS24 gradient in all IPI groups. The IPI24 also identified a significant percentage of patients with high risk disease, with over 20% of patients having a 50% or higher risk of failing to achieve EFS24. The IPI24 provides an individual patient level probability of achieving the clinically relevant EFS24 endpoint. It can be used via electronic apps. Am. J. Hematol. 91:179–184, 2016. © 2015 Wiley Periodicals, Inc.
Myeloproliferative neoplasms: A decade of discoveries and treatment advances
Tefferi, Ayalew

American Journal of Hematology | October 22, 2015 | Volume: 91 | Issue: 1 | Pages: 50-58

10.1002/ajh.24221 | PMID 26492355 Get It

Myeloproliferative neoplasms (MPN) are clonal stem cell diseases, first conceptualized in 1951 by William Dameshek, and historically included chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). In 1960, Nowell and Hungerford discovered an invariable association between the Philadelphia chromosome (subsequently shown to harbor the causalBCR‐ABL1mutation) and CML; accordingly, the term MPN is primarily reserved for PV, ET, and PMF, although it includes other related clinicopathologic entities, according to the World Health Organization (WHO) classification system. In 2005, William Vainchenker and others described a Janus kinase 2 mutation (JAK2V617F) in MPN and this was followed by a series of additional descriptions of mutations that directly or indirectly activate JAK‐STAT:JAK2exon 12, myeloproliferative leukemia virus oncogene (MPL) and calreticulin (CALR) mutations. The discovery of these, mostly mutually exclusive, “driver” mutations has contributed to revisions of the WHO diagnostic criteria and risk stratification in MPN. Mutations other thanJAK2,CALRandMPLhave also been described in MPN and shown to provide additional prognostic information. From the standpoint of treatment, over the last 50 years, Louis Wasserman from the Unites States and Tiziano Barbui from Italy had skillfully organized and led a number of important clinical trials, whose results form the basis for current treatment strategies in MPN. More recently, allogeneic stem cell transplant, as a potentially curative treatment modality, and JAK inhibitors, as palliative drugs, have been added to the overall therapeutic armamentarium in myelofibrosis. In the current review, I will summarize the important advances made in the last 10 years regarding the science and practice of MPN. Am. J. Hematol. 91:50–58, 2016. © 2015 Wiley Periodicals, Inc.
The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab
Huang, Raymond Y. , Rahman, Rifaquat , Felten, Sara J., Anderson, S. Keith , Nayak, Lakshmi , Lee, Eudocia Q. , Abrey, Lauren E. , Reardon, David A. , Pope, Whitney B. , Wen, Patrick Y. , Galanis, Evanthia , Ballman, Karla V. , Ellingson, Benjamin M. , Cloughesy, Timothy F. , Wen, Patrick Yung , Huang, Raymond

Clinical Cancer Research | October 22, 2015 | Volume: 22 | Issue: 3 | Pages: 575-581

10.1158/1078-0432.ccr-14-3040 | PMID 26490307 Get It

Abstract Purpose: The RANO criteria have not been assessed using outcome data from prospective trials. We examined the radiologic data of patients with recurrent glioblastoma from the randomized phase II trial (AVF3708g) to determine the effect of including T2/FLAIR evaluation as per RANO criteria on measurements of objective response rates (ORRs) and progression-free survival (PFS) compared with assessment based on contrast enhancement (Macdonald criteria). Experimental Design: The ORRs and median PFS were determined using the RANO criteria and compared with those obtained using the Macdonald criteria. Landmark analyses were performed at 2, 4, and 6 months, and Cox proportional hazard models were used to determine the associations between OR and progression with subsequent survival. Results: The ORRs were 0.331 [95% confidence interval (CI), 0.260–0.409] and 0.393 (95% CI, 0.317–0.472) by RANO and Macdonald criteria, respectively (P &lt; 0.0001). The median PFS was 4.6 months (95% CI, 4.1–5.5) using RANO criteria, compared with 6.4 months (95% CI, 5.5–7.1) as determined by Macdonald criteria (P = 0.01). At 2-, 4-, and 6-month landmarks, both OR status and PFS determined by either RANO or Macdonald criteria were predictive of overall survival [OS; hazard ratios for 4-month landmark (OR HR = 1.93, P = 0.0012; PFS HR, 4.23, P &lt; 0.0001)]. Conclusions: The inclusion of T2/FLAIR assessment resulted in statistically significant differences in median PFS and ORRs compared with assessment of solely enhancing tumor (Macdonald criteria), although OR and PFS determined by both RANO and Macdonald criteria correlated with OS. Clin Cancer Res; 22(3); 575–81. ©2015 AACR.
To beam or not to beam
Dronca, Roxana

Science Translational Medicine | October 22, 2015 | Volume: 7 | Issue: 310 | Pages: No page available

10.1126/scitranslmed.aad4448 Get It

Radiation therapy for prostate cancer can increase androgen receptor signaling and exacerbate the disease in some patients.
Defensive Perimeter in the Central Nervous System: Predominance of Astrocytes and Astrogliosis during Recovery from Varicella-Zoster Virus Encephalitis
Carpenter, John E., Clayton, Amy C., Halling, Kevin C. , Bonthius, Daniel J. , Buckingham, Erin M., Jackson, Wallen, Dotzler, Steven M. , Card, J. Patrick , Grose, Charles , Enquist, Lynn W.

Journal of Virology | October 22, 2015 | Volume: 90 | Issue: 1 | Pages: 379-391

10.1128/jvi.02389-15 | PMID 26491149 Get It

ABSTRACT Varicella-zoster virus (VZV) is a highly neurotropic virus that can cause infections in both the peripheral nervous system and the central nervous system. Several studies of VZV reactivation in the peripheral nervous system (herpes zoster) have been published, while exceedingly few investigations have been carried out in a human brain. Notably, there is no animal model for VZV infection of the central nervous system. In this report, we characterized the cellular environment in the temporal lobe of a human subject who recovered from focal VZV encephalitis. The approach included not only VZV DNA/RNA analyses but also a delineation of infected cell types (neurons, microglia, oligodendrocytes, and astrocytes). The average VZV genome copy number per cell was 5. Several VZV regulatory and structural gene transcripts and products were detected. When colocalization studies were performed to determine which cell types harbored the viral proteins, the majority of infected cells were astrocytes, including aggregates of astrocytes. Evidence of syncytium formation within the aggregates included the continuity of cytoplasm positive for the VZV glycoprotein H (gH) fusion-complex protein within a cellular profile with as many as 80 distinct nuclei. As with other causes of brain injury, these results suggested that astrocytes likely formed a defensive perimeter around foci of VZV infection (astrogliosis). Because of the rarity of brain samples from living humans with VZV encephalitis, we compared our VZV results with those found in a rat encephalitis model following infection with the closely related pseudorabies virus and observed similar perimeters of gliosis. IMPORTANCE Investigations of VZV-infected human brain from living immunocompetent human subjects are exceedingly rare. Therefore, much of our knowledge of VZV neuropathogenesis is gained from studies of VZV-infected brains obtained at autopsy from immunocompromised patients. These are not optimal samples with which to investigate a response by a human host to VZV infection. In this report, we examined both flash-frozen and paraffin-embedded formalin-fixed brain tissue of an otherwise healthy young male with focal VZV encephalitis, most likely acquired from VZV reactivation in the trigeminal ganglion. Of note, the cellular response to VZV infection mimicked the response to other causes of trauma to the brain, namely, an ingress of astrocytes and astrogliosis around an infectious focus. Many of the astrocytes themselves were infected; astrocytes aggregated in clusters. We postulate that astrogliosis represents a successful defense mechanism by an immunocompetent human host to eliminate VZV reactivation within neurons.
Transbronchial Lung Biopsy and Transthoracic Needle Aspiration
Sanderson, David

American Review of Respiratory Disease | October 22, 2015 | Volume: 122 | Issue: 5 | Pages: 667-667

10.1164/arrd.1980.122.5.667 | PMID 7447150 Get It

Post-traumatic stress disorder symptoms may explain poor mental health in patients with fibromyalgia
Whipple, Mary O. , Vincent, Ann , Toussaint, Loren , Whipple, Mary

Journal of Health Psychology | October 21, 2015 | Volume: 22 | Issue: 6 | Pages: 697-706

10.1177/1359105315611957 | PMID 26490627 Get It

Symptoms of post-traumatic stress disorder are common in fibromyalgia patients. This study compared post-traumatic stress disorder symptoms in fibromyalgia patients and healthy controls and determined whether patient-control differences in post-traumatic stress disorder symptoms mediated differences in mental health. In all, 30 patients and 30 healthy controls completed questionnaires assessing symptoms of post-traumatic stress disorder and mental health. Fibromyalgia patients had greater symptoms of post-traumatic stress disorder and mental health than controls. Patient-control differences in mental health symptoms were fully or partially mediated by differences in post-traumatic stress disorder symptoms. Healthcare providers should understand the role of trauma as management of trauma symptoms may be one strategy for improving mental health.